Sign in
Active, not recruitingNo phase

Fractional Exhaled Nitric Oxide as Possible Non - Invasive Biomarker to Assess Obstructive Sleep Apnea Severity

Key facts

Who runs it
Tanta University
Where
Egypt1 site in 1 countryChoose a country to see its sites
Trial code
Status
Active, not recruiting
People taking part
200 people, planned
Started
25 May 2026
Ended
1 Oct 2026
Type of study
Observational
Record updated
25 August 2026

Who can take part

Age
18 years to 70 years
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 8 criteriaShow less

Who can take part

  • Ages Eligible for study: 18 years till 70 years old
  • Newly suspected OSA patients with Epworth Sleepiness Scale (ESS) ≥ 10

Who cannot take part

  • Recent inhaled or systemic corticosteroids within the pasr 4 weeks
  • Any chronic Respiratory disorders other than OSA (asthma, COPD, allergic rhinitis, and atopic diseases)
  • Recent respiratory infection less than 4 weeks
  • Uncontrolled diabetes \& any chronic debilitating diseases (liver, renal, collagen diseases) Informed Consent will be taken from the participants before clinical examination
  • Younger age than 18 years
  • Current smokers

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Aim of work

Read full original descriptionShow less

1. Primary aim: Asses correlation between FeNO level, OSA severity 2. Secondary aim: Clarifying FeNO's role as a biomarker to assess airway inflammation, Cut off value prediction to moderate and severe OSA and its potential significance to improve clinical management strategies for OSA patients.

The group in the trial

  • • Control group AHI less than 5 \ hour - case groups Milld OSA & moderate to severe OSA

    All 200 participants will undergo: * History taking including: Age, sex, occupation, residence, education, and special habits e.g., smoking * Plain chest x ray\& PFT to exclude any other chest diseases (asthma\& COPD) * The participants' Blood pressure, height and weight will be measured, and body mass index will be calculated. * Daytime sleepiness will be assessed by the Epworth Sleepiness Scale and a value of 10 or more denoting as excessive daytime sleepiness. * Full laboratory investigation to exclude any chronic diseases. * Full-night PSG in chest department, Tanta university hospital. * FENO level base line at 9 am after PSG night \& interpretation accordin * After PSG result, cases will be divided in 3 groups * Control group AHI less than 5 \\ hour * Mild OSA group AHI than 5-15 \\ hour * Mod to severe OSA more than 15 \\ hour

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Record updated
25 August 2026